ERBB2 and breast carcinoma: engineered NK-92 cells to express a HER2/neu-targeting chimeric antigen receptor (CAR), radiolabelled them cells with [18F]FDG, and administered the cells into mice bearing HER2 + /neu breast cancer and were able to monitor the accumulation of these labeled cells in tumors [17].